Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 335

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia

Open access
Neviani, Paolo, Santhanam, Ramasamy, Oaks, Joshua J., Eiring, Anna M., Notari, Mario, Blaser, Bradley W., Liu, Shujun, Trotta, Rossana, Muthusamy, Natarajan, Gambacorti-Passerini, Carlo, Druker, Brian J., Cortes, Jorge, Marcucci, Guido, Chen, Ching-Shih, Verrills, Nicole M., Roy, Denis C., Caligiuri, Michael A., Bloomfield, Clara D., Byrd, John C., Perrotti, Danilo·2007·Journal of Clinical Investigation
DOI 10.1172/jci31095
Open this paper in CoChat — free account

Abstract

Blast crisis chronic myelogenous leukemia (CML-BC) and Philadelphia chromosome-positive (Ph1-positive) acute lymphocytic leukemia (ALL) are 2 fatal BCR/ABL-driven leukemias against which Abl kinase inhibitors fail to induce a long-term response. We recently reported that functional loss of protein phosphatase 2A (PP2A) activity is important for CML blastic transformation. We assessed the therapeutic potential of the PP2A activator FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride), an immunomodulator in Phase III trials for patients with multiple sclerosis or undergoing organ transplantation, in CML-BC and Ph1 ALL patient cells and in in vitro and in vivo models of these BCR/ABL+ leukemias. Our data indicate that FTY720 induces apoptosis and impairs clonogenicity of imatinib/dasatinib-sensitive and -resistant p210/p190(BCR/ABL) myeloid and lymphoid cell lines and CML-BC(CD34+) and Ph1 ALL(CD34+/CD19+) progenitors but not of normal CD34+ and CD34+/CD19+ bone marrow cells. Furthermore, pharmacologic doses of FTY720 remarkably suppress in vivo p210/p190(BCR/ABL)-driven [including p210/p190(BCR/ABL)(T315I)] leukemogenesis without exerting any toxicity. Altogether, these results highlight the therapeutic relevance of rescuing PP2A tumor suppressor activity in Ph1 leukemias and strongly support the introduction of the PP2A activator FTY720 in the treatment of CML-BC and Ph1 ALL patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci31095

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 72 references

Research works printed but not linked: 14

  1. Savage, 1997, Br. J. Haematol., 96, 111, 10.1046/j.1365-2141.1997.d01-1982.x · doi:10.1046/j.1365-2141.1997.d01-1982.x
  2. Cohen, 2005, Clin. Cancer Res., 11, 12, 10.1158/1078-0432.12.11.1 · doi:10.1158/1078-0432.12.11.1
  3. Deininger, 2005, Blood (ASH Annual Meeting Abstracts)., 106, 691
  4. Brinkmann, 2004, Yonsei Med. J., 45, 991, 10.3349/ymj.2004.45.6.991 · doi:10.3349/ymj.2004.45.6.991
  5. Dumont, 2005, IDrugs., 8, 236
  6. Skerjanec, 2005, J. Clin. Pharmacol., 45, 1268, 10.1177/0091270005279799 · doi:10.1177/0091270005279799
  7. Janssens, 2001, Biochem. J., 353, 417, 10.1042/bj3530417 · DOI · Paper page
  8. French, 2003, Cancer Res., 63, 5962
  9. Azuma, 2002, Cancer Res., 62, 1410
  10. Xin, 2004, Br. J. Pharmacol., 143, 581, 10.1038/sj.bjp.0705980 · doi:10.1038/sj.bjp.0705980
  11. Suzuki, 2004, Proc. Natl. Acad. Sci. U. S. A., 101, 14788, 10.1073/pnas.0406536101 · doi:10.1073/pnas.0406536101
  12. 10.1172/JCI200316950 · doi:10.1172/jci200316950
  13. Cross, 1994, Leukemia., 8, 186
  14. Hattori, 1995, Leuk. Res., 19, 389, 10.1016/0145-2126(95)00004-8 · doi:10.1016/0145-2126(95)00004-8

Cited by

See all 335

Metadata

Authors
Neviani, P., Santhanam, R., Oaks, J. J., Eiring, A. M., Notari, M., Blaser, B. W., Liu, S., Trotta, R., Muthusamy, N., Gambacorti-Passerini, C., Druker, B. J., Cortes, J., Marcucci, G., Chen, C.-S., Verrills, N. M., Roy, D. C., Caligiuri, M. A., Bloomfield, C. D., Byrd, J. C., & Perrotti, D.
Venue
Journal of Clinical Investigation
Publisher
American Society for Clinical Investigation
Published
2007-09-04
Volume
117
Issue
9
Pages
2408-2421
ISSN
0021-9738 (ISSN-L)
DOI
10.1172/jci31095
OpenAlex
W1975748957
Cited by
335
References
72
FWCI
14.19
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia. https://app.cochat.ai/papers/10.1172/jci31095
The paper
Neviani, P., Santhanam, R., Oaks, J. J., Eiring, A. M., Notari, M., Blaser, B. W., Liu, S., Trotta, R., Muthusamy, N., Gambacorti-Passerini, C., Druker, B. J., Cortes, J., Marcucci, G., Chen, C.-S., Verrills, N. M., Roy, D. C., Caligiuri, M. A., Bloomfield, C. D., Byrd, J. C., & Perrotti, D. (2007). FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia. Journal of Clinical Investigation. https://doi.org/10.1172/jci31095

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.